Cancer News, Research & Analysis
Time-sensitive and reliable coverage of pharmaceutical industry
developments, clinical trials, treatments and cures worldwide
| For 24/7 unlimited access... | |
|---|---|
Subscribe now
|
or call us on: +43 (0)1 71 72 8 900 (Vienna) or on: +44 (0)20 7769 6707 (London) |
Pricing
Our pricing options are simple. There is one structure for corporates/professionals, and another special discounted structure for patients.
1. Corporates/Professionals (Healthcare & Pharmaceutical)
For corporates/professionals the service costs €750/£675 a year per user.
Corporates/professionals can subscribe to Cancer Stat by contacting us directly:
- by email: cancerstat@templetonapus.com
- by phone:
Vienna head office, Austria, European Union: +43 (0)1 71 71 8 900
London office, United Kingdom: +44 (0)20 7769 6707
You have the option of taking a 3 week free trial to Cancer Stat before subscribing.
2. Patients
Patients can subscribe to Cancer Stat at a special discounted rate by either of the following methods:
a. Making a single payment of £240 for a year's subscription via PayPal.
b. Paying £30 a month for an ongoing monthly subscription via PayPal.
Both options provide you with your own personal Cancer Stat account and can be found at: www.cancerstat.com/accounts/subscribe
You will have full access to all platform features and to the extensive email services. You can also request that drugs or treatments that are of special interest to you are added and tracked.
After signing up:
1. You will receive by email your login ID and password within 3 hours.
2. The email will include a weblink with a 10 minute video demo explaining how to most effectively use your Cancer Stat account.
3. You will be asked in the email if you have any specific information content requests.
Payments
1. Corporates/Professionals (Healthcare & Pharmaceutical)
Corporates/professionals will be invoiced.
2. Patients/Family
Patients/family can make secure payments using credit or debit cards via PayPal at: www.cancerstat.com/accounts/subscribe
Most viewed
- 1. Disulfiram Alone Functions as a Radiosensitizer for Pancreatic Cancer Both In Vitro and In Vivo
- 2. Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
- 3. A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
- 4. Prediction of Biochemical Recurrence-Free Survival of Prostate Cancer Patients Leveraging Multiple Gene Expression Profiles in Tumor Microenvironment
- 5. The smart toilet era is here! Are you ready to share your analprint with big tech?
- 6. Zymo Research Receives CE IVD Mark for its EZ DNA Methylation-Lightning Kit
- 7. Why do we need better omics in the breast cancer care?
- 8. CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors
- 9. Soon-Shiong to Back Cancer, Covid Vaccines in South Africa
- 10. Aira Matrix develops AI-based platform for prostate cancer from screening to post-surgical follow ups
Last updated at 23:48 GMT
Hot News Makers
Health/Pharma Companies
-
52151.43
-
31605.63
-
23630.21
-
14455.36
-
11940.90
-
11620.74
-
9949.06
-
9139.41
-
7157.81
-
7109.07
Last updated at 23:10 GMT